Literature DB >> 25332613

Receptor conversion in carcinoma breast metastatic to the bone marrow.

T Santosh1, M K Patro1, J Nayak1, A K Bal1, A Choudhury1, B Behera1, D P Mishra1.   

Abstract

Breast cancer is the first in the incidence of malignancies among women. The documented frequency of osseous metastasis from breast cancer is about 12.8 %. Although breast cancer cells have been documented in the bone marrow in autopsy, haematological manifestations due to metastatic disease to the marrow is rare. The prognosis of these cases is dismal and improper management worsen the condition further. IHC for ER, PR & Her 2/neu status plays a vital role in ascertaining the treatment protocol both in primary tumors as well as metastatic or recurrent tumors. Receptor conversion has been documented in metastatic and recurrent cases. We report a case of 65 year female with a history of ER, PR positive and Her 2/neu negative carcinoma breast 3½ years back, presented with anemia and low back ache diagnosed as metastatic breast carcinoma to bone marrow with receptor conversion.

Entities:  

Keywords:  Immunohistochemistry; Metastatic breast carcinoma; Receptor Conversion

Year:  2014        PMID: 25332613      PMCID: PMC4192187          DOI: 10.1007/s12288-014-0394-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  10 in total

Review 1.  Treatment of breast cancer.

Authors:  G N Hortobagyi
Journal:  N Engl J Med       Date:  1998-10-01       Impact factor: 91.245

2.  Impact of metastatic estrogen receptor and progesterone receptor status on survival.

Authors:  Elyse E Lower; Eleanor L Glass; Deborah A Bradley; Robbin Blau; Sue Heffelfinger
Journal:  Breast Cancer Res Treat       Date:  2005-03       Impact factor: 4.872

3.  Factors influencing visualization of vertebral metastases on MR imaging versus bone scintigraphy.

Authors:  T Taoka; N A Mayr; H J Lee; W T Yuh; T M Simonson; K Rezai; K S Berbaum
Journal:  AJR Am J Roentgenol       Date:  2001-06       Impact factor: 3.959

4.  HER-2/neu expression in primary and metastatic breast cancer.

Authors:  Elyse E Lower; Eleanor Glass; Robbin Blau; Stacy Harman
Journal:  Breast Cancer Res Treat       Date:  2008-02-14       Impact factor: 4.872

5.  Variation in receptor status between primary and metastatic breast cancer.

Authors:  I M Holdaway; J V Bowditch
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

Review 6.  Breast cancer metastasis to bone: it is not all about PTHrP.

Authors:  Manali Bendre; Dana Gaddy; Richard W Nicholas; Larry J Suva
Journal:  Clin Orthop Relat Res       Date:  2003-10       Impact factor: 4.176

7.  Receptor conversion in distant breast cancer metastases.

Authors:  Laurien D C Hoefnagel; Marc J van de Vijver; Henk-Jan van Slooten; Pieter Wesseling; Jelle Wesseling; Pieter J Westenend; Joost Bart; Cornelis A Seldenrijk; Iris D Nagtegaal; Joost Oudejans; Paul van der Valk; Petra van der Groep; Elisabeth G E de Vries; Elsken van der Wall; Paul J van Diest
Journal:  Breast Cancer Res       Date:  2010-09-23       Impact factor: 6.466

8.  The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: a clinical study of 19 cases.

Authors:  Fahir Ozkalemkas; Ridvan Ali; Vildan Ozkocaman; Tulay Ozcelik; Ulku Ozan; Hulya Ozturk; Ender Kurt; Turkkan Evrensel; Omer Yerci; Ahmet Tunali
Journal:  BMC Cancer       Date:  2005-11-01       Impact factor: 4.430

Review 9.  The changing global patterns of female breast cancer incidence and mortality.

Authors:  Freddie Bray; Peter McCarron; D Maxwell Parkin
Journal:  Breast Cancer Res       Date:  2004-08-26       Impact factor: 6.466

10.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors:  A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2009-06-17       Impact factor: 32.976

  10 in total
  1 in total

1.  Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients.

Authors:  Thi Hoa Nguyen; Van Hung Nguyen; Thanh Long Nguyen; Cai Qiuyin; Thi Huyen Phung
Journal:  Biomed Res Int       Date:  2019-09-10       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.